Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
Status:
RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
This is a pilot study to determine feasibility and safety of the combination of Dendritic Cell (DC1) vaccines and elacestrant in patients with hormone positive HER2 negative metastatic breast cancer.
Phase:
PHASE1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute